Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Acadia Expects Broad Nuplazid Reimbursement; Pricing Soon

Executive Summary

Acadia Pharmaceuticals Inc. has not yet priced its newly approved Parkinson's disease psychosis (PDP) drug Nuplazid (pimavanserin), but anticipates it will be covered by a vast majority of payers. The PDP approval also sets the stage for expanding Nuplazid's use into other indications, including Alzheimer's disease psychosis and agitation.

Advertisement

Related Content

Acadia's Nuplazid OK'd; A Billion Dollar Parkinson's Drug?
Focus Turns To Label After Panel Backs Acadia's Nuplazid
Panel To Ponder Nuplazid's Clinical Meaningfulness
Parkinson's Needs FDA Flexibility, NIH Funding Certainty
FDA dubs Acadia Parkinson's drug Nuplazid 'breakthrough'

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC065099

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel